Ann: Prima Newsletter , page-2

An excellent read...the news just keeps getting better and better, as does the language used in the announcements.
Some key points:

"The objective of the trial is to further confirm the ability of CVac? to reduce the instance of relapse in ovarian cancer patients, control the metastases of the cancer and increase the life expectancy of patients."

"Subject to required regulatory steps being finalised, Prima expects the first sales of CVacTM in DHCC to commence before the end of 2011. This will allow the Company to begin treatment of ovarian cancer patients and to generate revenues in a growing Middle Eastern healthcare market"

"In the future, the parties also aim to pursue the potential to extend the application of CVacTM in Dubai to other mucin-1 positive tumours ? and treat other types of cancer."

"In addition to the opportunity to provide CVacTM on a
commercial scale for the first time, the Company views
the approval to market and distribute CVacTM in this region
as an ideal complement to its core focus of its upcoming
Phase III Trial."

"In the case of Provenge ?, the vaccine targets prostate cancer only. The cells are injected into a vein, whereas CVac ? is injected under the skin where it finds T cells in large numbers"

"The COGI meeting was attended by key opinion leaders(KOL) and other important people in the gynecology oncology space, and Dr Frazer?s CVac? presentation was most timely, given the late stage nature of CVac??s trial process and the audience in attendance.
The presentation was extremely well received and served
to underline Prima?s intention to develop CVac? as a viable
treatment option in the multi billion dollar pharmacy
oncology market."

"DO VACCINES WORK TO
PREVENT CANCER?
They may do in the future."